Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Finranks

Компания

  • О нас

Контакты

  • [email protected]

Мы в соцсетях

  • Instagram
  • Telegram
  • LinkedIn

Все права защищены.

Условия использования
  • Главная
  • Рынки
  • Скринер
  • Новости
  • О нас
  1. Home
  2. CAH

(CAH)

NYQ – Цена в реальном времени. Валюта: USD

206.58

-1.12 (-0.54%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

204.62

-1.96 (-0.95%)

После закрытия: Mar 27, 2026, 7:57 PM EDT

  • Обзор
  • Новости
  • График
  • Финансы
  • Дивиденды
  • Прогноз
  • Владельцы
  • Профиль
Cardinal Health vs. McKesson: Which Healthcare Giant Is the Smarter Bet?
24.03.2026

Cardinal Health vs. McKesson: Which Healthcare Giant Is the Smarter Bet?

CAH's turnaround gains traction with strong earnings growth and margin expansion, outpacing MCK's steady performance outlook.

Cardinal Health to Announce Third-Quarter Results for Fiscal Year 2026 on April 30
24.03.2026

Cardinal Health to Announce Third-Quarter Results for Fiscal Year 2026 on April 30

DUBLIN, Ohio, March 24, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release third-quarter financial results for its fiscal year 2026 on April 30 as previously indicated, prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m.

Are GLP-1 Drugs Becoming a Meaningful Revenue Driver for CAH Stock?
23.03.2026

Are GLP-1 Drugs Becoming a Meaningful Revenue Driver for CAH Stock?

CAH sees GLP-1 drugs boost revenue growth, but margins lag as strong demand lifts volumes without significantly improving profitability.

Wall Street Analysts Think Cardinal (CAH) Is a Good Investment: Is It?
23.03.2026

Wall Street Analysts Think Cardinal (CAH) Is a Good Investment: Is It?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Cardinal Health Appoints Patricia A. Hemingway Hall as Board Chair
23.03.2026

Cardinal Health Appoints Patricia A. Hemingway Hall as Board Chair

DUBLIN, Ohio, March 23, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today announced that its Board of Directors has appointed Patricia A. Hemingway Hall to succeed Gregory B.

CAH Posts Strong Cash Flow, Eyes Next Steps in Capital Deployment
19.03.2026

CAH Posts Strong Cash Flow, Eyes Next Steps in Capital Deployment

CAH's $1.8 billion free cash flow fuels buybacks, dividends, and reinvestment, as Cardinal Health eyes disciplined capital deployment and targeted growth opportunities.

Cardinal Health (CAH) is a Top-Ranked Value Stock: Should You Buy?
19.03.2026

Cardinal Health (CAH) is a Top-Ranked Value Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Видео

03.11.2025
Neutral
Cardinal Health CEO says Obamacare subsidies extension under review 'every single day'

Пресс-релизы

Cardinal Health Appoints Patricia A. Hemingway Hall as Board Chair
23.03.2026

Cardinal Health Appoints Patricia A. Hemingway Hall as Board Chair

DUBLIN, Ohio, March 23, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today announced that its Board of Directors has appointed Patricia A. Hemingway Hall to succeed Gregory B.

Cardinal Health report highlights cost savings and provider confidence in biosimilars
24.02.2026

Cardinal Health report highlights cost savings and provider confidence in biosimilars

New analysis shows biosimilars are projected to strengthen cost savings and provider confidence across the healthcare ecosystem, with oncology leading in adoption and accessibility gains. DUBLIN, Ohio, Feb. 24, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today released its 2026 Biosimilars Report: Driving access and patient outcomes in physician practices, which highlights the substantial savings biosimilars have delivered to the U.S. healthcare system and the strong confidence providers have in these treatments.

Cardinal Health Board of Directors Approves Quarterly Dividend
12.02.2026

Cardinal Health Board of Directors Approves Quarterly Dividend

DUBLIN, Ohio, Feb. 12, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on April 15, 2026 to shareholders of record at the close of business on April 1, 2026.

Cardinal Health Reports Second Quarter Fiscal Year 2026 Results and Raises Outlook
05.02.2026

Cardinal Health Reports Second Quarter Fiscal Year 2026 Results and Raises Outlook

Revenue increased 19% to $65.6 billion GAAP 1 operating earnings increased 29% to $707 million; GAAP diluted EPS increased 19% to $1.97 Non-GAAP operating earnings increased 38% to $877 million; non-GAAP diluted EPS increased 36% to $2.63 Cardinal Health raises fiscal year 2026 non-GAAP EPS guidance2 to $10.15 to $10.35 Cardinal Health completes annual baseline share repurchase of $750 million Cardinal Health reaches targeted leverage range 3 DUBLIN, Ohio, Feb. 5, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported second quarter fiscal year 2026 revenues of $65.6 billion, an increase of 19% from the second quarter of fiscal year 2025. Second quarter GAAP operating earnings increased 29% to $707 million and GAAP diluted earnings per share (EPS) increased 19% to $1.97.